Completed

NCT Number: NCT01630109

Study of Metoclopramide in Small Bowel Capsule Endoscopy

Patients undergoing small bowel capsule endoscopy will be randomized into 3 study groups to either receive 5 mg of metoclopramide, 10 mg of metoclopramide, or a placebo 30 minutes prior to swallowing the Pill Cam. This is a randomized, double-blind, placebo-controlled design. The outcomes to be assessed are capsule study completion rates, gastric transit time, small bowel transit time, and the effect of diabetes on pill capsule completion rates. The purpose of the study is to assess if metoclopramide given prior to pill capsule endoscopy has any effect on pill capsule completion rate, gastric transit time, small bowel transit time, and pill capsule completion rates in diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pill Capsule Endoscopy Completion Rates

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Genesys Regional Medical Center

Grand Blanc, Michigan, 48439, United States

About this study

Pill Capsule Endoscopy allows Gastroenterologists to visualize the mucosa of the small bowel beyond the reach of any endoscope and to an extent never before possible. It involves the ingestion of a small pill camera approximately the size of a large vitamin. 8 hours of images are transmitted to a sensor worn around the patient's waist. At the conclusion of the test, these images are downloaded to a computer for physician review. Meanwhile, the PillCam™ passes naturally through the digestive system and does not require retrieval.

Many of these pill capsule studies are incomplete due to failure of the pill capsule to reach the colon. Metoclopramide (brand name Reglan) is an anti-emetic that also has known pro-motility effects in the GI tract. The thought behind this study is that metoclopramide will increase the rate of passage of the pill capsule through the GI tract allowing a higher completion rate of the pill capsule studies.

Patients scheduled for pill capsule endoscopy will be approached on the morning of their procedure to inform them of the research study. After proper consent is obtained the patient will receive either 5 mg Metoclopramide, 10 mg Metoclopramide, or a placebo pill 30 minutes prior to their pill capsule study. The pill capsule camera records 8 hours worth of data. The patient will return at the conclusion of their study to turn in their recorder. The ordering gastroenterologist will then read the study. Information regarding pill capsule completion (pill capsule goes through the ileocecal valve), gastric transit time, and small bowel transit time will then be recorded and analyzed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and women over the age of 18 undergoing pill capsule endoscopy to investigate unexplained rectal bleeding, anemia, iron deficiency, abdominal pain, altered bowel habits, and/or weight loss.

Exclusion criteria

Inability to sign consent for research participation
Inability to swallow PillCam™, placebo, or metoclopramide capsule
Known hypersensitivity/allergy to metoclopramide
Active congestive heart failure or respiratory failure requiring ventilator assistance
Presence of cardiac pacemaker or implanted electromedical device
Known bowel obstruction/stricture/fistula or intrauterine pregnancy
Known history of Whipple procedure (pancreaticoduodenectomy), Billroth II surgery (partial gastrectomy with gastrojejunostomy), or gastric bypass surgery due to risk of capsule retention in a blind intestinal limb necessitating surgical retrieval
Known history of seizure disorder, renal failure requiring dialysis, or pheochromocytoma
Lactating women

Treatment and study plan

Metoclopramide

Drug

A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.

Other names: Brand name of Metoclopramide is Reglan

Placebo

Drug

A placebo capsule made to look like the metoclopramide capsule.

Primary outcomes

Difference in Treatment vs. Placebo in Pill Capsule Completion Rates

Time frame: 12 hours

This study is investigating whether there is a difference in pill capsule completion rates between a treatment group (metoclopramide) vs. placebo. It is also looking at differences in completion rates between two different doses of metoclopramide (5 mg vs. 10 mg).

Secondary outcomes

Differences in Gastric Transit Time in Treatment vs. Placebo in Pill Capsule Studies

Time frame: 12 hours

This study will investigate whether treatment with metoclopramide (5 mg or 10 mg) vs. placebo will affect gastric transit time.
Differences in Small Bowel Transit Time in Treatment vs. Placebo in Pill Capsule Studies

Time frame: 12 hours

This study will investigate whether there is a difference in small bowel transit time in pill capsule studies with treatment with metoclopramide (5 mg or 10 mg) vs. placebo.
Difference in Pill Capsule Completion Rates in Diabetics vs. Non-diabetics

Time frame: 12 hours

This study will investigate whether there is any difference in pill capsule completion rates in patients who are diabetic vs. those who are not diabetic.

Sponsors and collaborators

Lead sponsor

Ascension Health

Industry

Registry information

Official study title

Metoclopramide As An Adjunct To Small Bowel Capsule Endoscopy: Rate of Complete Evaluation And Affect on Transit Times

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Jun 28, 2012
Registry last updated: Feb 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.